Gnosis by Lesaffre launches phages-based ingredient line for gut health
The first product, developed from a new technological platform from Lesaffre that targets the main drivers of pathogen—induced digestive issues—is intended to fight pathogenic bacteria responsible for serious infections.
Gnosis by Lesaffre (Marcq-En-Baroeul, France) introduceda phages-based ingredient line to help target specific pro-inflammatory or pathogenic bacteria in the gut and potentially enhance the gastrointestinal benefits of probiotics.
“Consumers recognize probiotics and how they support our digestive health and overall health,” said Philippe Caillat, Gnosis by Lesaffre’sglobal marketing director, in a press release. “That’s what pushed us to continue exploring solutions for targeted digestive disorders, such as abdominal pain, diarrhea, and gut flora restoration. Good gut health truly is the essence of a good life. We’re here to bring that to life with our new phages-based portfolio.”
The first product, developed from a new technological platform fromLesaffrethat targets the main drivers of pathogen—induced digestive issues—is intended to fight pathogenic bacteria responsible for serious infections such as E.coli, Salmonella, and Listeria.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
